Role of trabectedin in the treatment of soft tissue sarcoma.

Détails

Ressource 1Télécharger: BIB_F99B330D2A0B.P001.pdf (199.45 [Ko])
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_F99B330D2A0B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Role of trabectedin in the treatment of soft tissue sarcoma.
Périodique
Oncotargets and Therapy
Auteur(s)
Christinat A., Leyvraz S.
ISSN
1178-6930 (Electronic)
ISSN-L
1178-6930
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
2
Numéro
9
Pages
105-113
Langue
anglais
Notes
Publication types: Journal Article
WOS Document Type: Review
Résumé
Interest in marine natural products has allowed the discovery of new drugs and trabectedin (ET-743, Yondelis), derived from the marine tunicate Ecteinascidia turbinata, was approved for clinical use in 2007. It binds to the DNA minor groove leading to interferences with the intracellular transcription pathways and DNA-repair proteins. In vitro antitumor activity was demonstrated against various cancer cell lines and soft tissue sarcoma cell lines. In phase I studies tumor responses were observed also in osteosarcomas and different soft tissue sarcoma subtypes. The most common toxicities were myelosuppression and transient elevation of liver function tests, which could be reduced by dexamethasone premedication. The efficacy of trabectedin was established in three phase II studies where it was administered at 1.5 mg/m2 as a 24 h intravenous infusion repeated every three weeks, in previously treated patients. The objective response rate was 3.7%-8.3% and the tumor control rate (which included complete response, partial response and stable disease) was obtained in half of patients for a median overall survival reaching 12 months. In nonpretreated patients the overall response rate was 17%. Twenty-four percent of patients were without progression at six months. The median overall survival was almost 16 months with 72% surviving at one year. Predictive factors of response are being explored to identify patients who are most likely to respond to trabectedin. Combination with other agents are currently studied with promising results. In summary trabectedin is an active new chemotherapeutic agents that has demonstrated its role in the armamentarium of treatments for patients with sarcomas.
Mots-clé
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 4, Cytarabine/administration & dosage, Dexamethasone/administration & dosage, Disease-Free Survival, Female, Follow-Up Studies, Genetic Heterogeneity, Hemoglobins, Humans, Male, Middle Aged, Multiple Myeloma/drug therapy, Multiple Myeloma/genetics, Multivariate Analysis, Prognosis, Retrospective Studies, Translocation, Genetic, Vincristine/administration & dosage, beta 2-Microglobulin/blood
Pubmed
Web of science
Création de la notice
08/10/2011 18:58
Dernière modification de la notice
03/03/2018 22:54
Données d'usage